It is provided a process for the preparation of bimatoprost, which comprises: a) reacting a compound of formula (III) with ethylamine in the presence of a suitable solvent; and b) deprotecting compound obtained in step a) to obtain bimatoprost, wherein R.sup.1 is selected from (C.sub.1-C.sub.16)alkyl, (C.sub.1C.sub.16)haloalkyl, (C.sub.2-C.sub.16)alkenyl, (C.sub.2-C.sub.16)haloalkenyl, (C.sub.1-C.sub.16)alkoxy(C.sub.1-C.sub.16)alkyl, aryl, (C.sub.1-C.sub.16)alkylaryl, allyl, (CH.sub.2CH.sub.2O).sub.nCH.sub.3 wherein n=1, 2, 3 or 4, and CH(OCH.sub.2CH.sub.2).sub.2; R.sub.2 is selected from H, (C.sub.1-C.sub.16)alkyl, (C.sub.1-C.sub.16)haloalkyl, (C.sub.2-C.sub.16)alkenyl, (C.sub.2-C.sub.16)haloalkenyl, (C.sub.1-C.sub.16)alkoxy(CrC.sub.16)alkyl, aryl, (C.sub.1-C.sub.16)alkylaryl, allyl; or, alternatively, R.sup.1 and R.sup.2 taken together are selected from CH.sub.2CH.sub.2CH.sub.2, CH.sub.2CH.sub.2, OCH.sub.2CH.sub.2, and OCHCH. There are also provided intermediates useful in such preparation process.

##STR00001##

It is provided a process for the preparation of bimatoprost, which comprises: a) reacting a compound of formula (III) with ethylamine in the presence of a suitable solvent; and b) deprotecting compound obtained in step a) to obtain bimatoprost, wherein R.sup.1 is selected from (C.sub.1-C.sub.16)alkyl, (C.sub.1C.sub.16)haloalkyl, (C.sub.2-C.sub.16)alkenyl, (C.sub.2-C.sub.16)haloalkenyl, (C.sub.1-C.sub.16)alkoxy(C.sub.1-C.sub.16)alkyl, aryl, (C.sub.1-C.sub.16)alkylaryl, allyl, (CH.sub.2CH.sub.2O).sub.nCH.sub.3 wherein n=1, 2, 3 or 4, and CH(OCH.sub.2CH.sub.2).sub.2; R.sub.2 is selected from H, (C.sub.1-C.sub.16)alkyl, (C.sub.1-C.sub.16)haloalkyl, (C.sub.2-C.sub.16)alkenyl, (C.sub.2-C.sub.16)haloalkenyl, (C.sub.1-C.sub.16)alkoxy(CrC.sub.16)alkyl, aryl, (C.sub.1-C.sub.16)alkylaryl, allyl; or, alternatively, R.sup.1 and R.sup.2 taken together are selected from CH.sub.2CH.sub.2CH.sub.2, CH.sub.2CH.sub.2, OCH.sub.2CH.sub.2, and OCHCH. There are also provided intermediates useful in such preparation process.

##STR00001##

A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.

A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing. Pharmaceutical composition containing antagonists. Methods employing antagonists and agonists for modulation of quorum sensing. Compounds are exemplified by those of formula:

A-[Z].sub.n-L1-[Y].sub.q-W-[V].sub.m-L2-HG,

where A is an acyclic aliphatic group, and HG is an optionally substituted phenyl group. Compounds include those where m and n are both 0, W is NH, Y is present and is COCH.sub.2CO, and L1 and L2 independently are [CH.sub.2].sub.p1 and [CH.sub.2].sub.p2, where p1 and p2, independently, are 0 or integers ranging from 1-10.

The present invention relates to N-(5-arylamido-2-methylphenyl)-5-methylisoquoxazole-4-carboxamide derivative, or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising same. The compound according to the present invention exhibits an FMS kinase inhibitory activity and thus can be used as pharmaceutical composition for preventing and treating diseases associated therewith.

The present invention relates to N-(5-arylamido-2-methylphenyl)-5-methylisoquoxazole-4-carboxamide derivative, or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising same. The compound according to the present invention exhibits an FMS kinase inhibitory activity and thus can be used as pharmaceutical composition for preventing and treating diseases associated therewith.

A compound of Formula 1 ##STR00001## wherein R.sub.1 represents hydrogen, halo, a C1-C4 alkyl group, a C1-C4 alkylhalide group, a C1-C4 alkoxy-C2-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group or a C3-C7 cycloalkyl group; R.sub.2 represents ##STR00002##
or a tautomer thereof; and R.sub.3 represents hydrogen, a C1-C4 alkyl group, a C1-C4 alkoxy-C2-C4 alkyl group or a C3-C7 cycloalkyl group; or a pharmaceutically acceptable salt or solvate thereof. Processes to prepare said compounds and novel intermediates are also claimed. Such compound finds utility in treating neuropathic pain and disorders of the central nervous system.

A compound of Formula 1 ##STR00001## wherein R.sub.1 represents hydrogen, halo, a C1-C4 alkyl group, a C1-C4 alkylhalide group, a C1-C4 alkoxy-C2-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group or a C3-C7 cycloalkyl group; R.sub.2 represents ##STR00002##
or a tautomer thereof; and R.sub.3 represents hydrogen, a C1-C4 alkyl group, a C1-C4 alkoxy-C2-C4 alkyl group or a C3-C7 cycloalkyl group; or a pharmaceutically acceptable salt or solvate thereof. Processes to prepare said compounds and novel intermediates are also claimed. Such compound finds utility in treating neuropathic pain and disorders of the central nervous system.